Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Myovant Sciences Ltd (MYOV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8170)・商品コード:DATA904C8170
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:35
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Myovant Sciences Ltd (Myovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist targeting conditions such as heavy menstrual bleeding associated with uterine fibroids and others. It also offers MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation in assisted reproduction. The company has operations in the US, Ireland and Switzerland. Myovant is headquartered in London, the UK.

Myovant Sciences Ltd (MYOV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10
Partnerships 12
Myovant Sciences Enters into Agreement with Flo Health 12
Myovant Sciences Enters into Option Agreement with Roivant Sciences 13
Licensing Agreements 14
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15
Equity Offering 16
Myovant Sciences Raises USD75 Million in Public Offering of Shares 16
Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18
Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19
Myovant Sciences Completes IPO for USD217.5 Million 20
Myovant Sciences Ltd – Key Competitors 22
Myovant Sciences Ltd – Key Employees 23
Myovant Sciences Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 07, 2018: Myovant Sciences reports financial results for first fiscal quarter ended June 30, 2018 25
Jun 07, 2018: Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018 26
Feb 13, 2018: Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017 28
Nov 13, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017 30
Aug 10, 2017: Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017 32
Corporate Communications 34
Jul 19, 2017: Myovant Bolsters Executive Team with Key Management Appointments 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Myovant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Myovant Sciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Myovant Sciences Raises USD100 Million in Financing of Shares and Notes 10
Myovant Sciences Enters into Agreement with Flo Health 12
Myovant Sciences Enters into Option Agreement with Roivant Sciences 13
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 14
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 15
Myovant Sciences Raises USD75 Million in Public Offering of Shares 16
Myovant Sciences Raises USD22.5 Million in Private Placement of Shares 18
Myovant Sciences Plans to Raise up to USD300 Million in Public Offering of shares 19
Myovant Sciences Completes IPO for USD217.5 Million 20
Myovant Sciences Ltd, Key Competitors 22
Myovant Sciences Ltd, Key Employees 23
Myovant Sciences Ltd, Subsidiaries 24

List of Figures
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Myovant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8170)販売に関する免責事項を必ずご確認ください。
★調査レポート[Myovant Sciences Ltd (MYOV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆